Dr. Oliver Scholle

  • September 2020 PhD degree at the University of Bremen (Title: "Utilization of pharmacological and non-pharmacological treatment in children and adolescents with attention deficit/hyperactivity disorder: Analyses based on primary and secondary data")
  • since October 2014 Research Fellow at Leibniz Institute for Prevention Research and Epidemiology – BIPS in the department Clinical Epidemiology
  • March 2012 – October 2014 Master of Science in Consumer Health Care (Charité, Berlin).
    Master thesis at BIPS in the department Clinical Epidemiology, Unit Drug Safety: "Comedication with antipsychotics and antidepressants of ADHD children and adolescents: a population-based cohort study"
  • July 2012 – September 2014 Nationwide locum pharmacist
  • April 2010 – April 2012 Employee in a pharmacy
  • October 2010 – March 2019 Employment in and initiation of the internet platform pharma4u
  • December 2008 – June 2009 Diploma thesis at the Institute of Clinical and Experimental Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel: "Development of a LC/MS method for analysing Piritramide in plasma"
  • October 2003 – November 2008 Study of Pharmacy at the Universities of Marburg and Kiel

  • Health Services Research
  • Drug Utilization Research
  • Pharmacoepidemiology
  • Neuropsychiatric diseases (particularly ADHD)

    ORCID logo

    Selected BIPS-Publications

  • Articles with peer review

  • Scholle O, Rasmussen L, Reilev M, Viebrock J, Haug U. Comparative analysis of outpatient antibiotic prescribing in early life: A population-based study across birth cohorts in Denmark and Germany. Infectious Diseases and Therapy. 2024;13(2):299-312.
    https://doi.org/10.1007/s40121-024-00916-3
  • Wharton GT, Becker C, Bennett D, Burcu M, Bushnell G, Ferrajolo C, Kaplan S, McMahon AW, Movva N, Raman SR, Scholle O, Suh M, Sun JW, Horton DB. Overview of global real-world data sources for pediatric pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety. 2024;33(1):e5695.
    https://doi.org/10.1002/pds.5695
  • Dörks M, Bachmann CJ, Below M, Hoffmann F, Paschke LM, Scholle O. Trends in antipsychotic use among children and adolescents in Germany: A study using 2011-2020 nationwide outpatient claims data. Frontiers in Psychiatry. 2023;14:1264047.
    https://doi.org/10.3389/fpsyt.2023.1264047
  • Scholle O, Asendorf M, Buck C, Grill S, Jones C, Kollhorst B, Riedel O, Schüz B, Haug U. Regional variations in outpatient antibiotic prescribing in Germany: A small area analysis based on claims data. Antibiotics. 2022;11(7):836.
    https://doi.org/10.3390/antibiotics11070836
  • Riedel O, Klau S, Langner I, Bachmann CJ, Scholle O. Prevalence of multimodal treatment in children and adolescents with ADHD in Germany: A nationwide study based on health insurance data. Child and Adolescent Psychiatry and Mental Health. 2021;15:76.
    https://doi.org/10.1186/s13034-021-00431-0
  • Scholle O, Kollhorst B, Riedel O, Bachmann CJ. First-time users of ADHD medication among children and adolescents in Germany: An evaluation of adherence to prescribing guidelines based on claims data. Frontiers in Psychiatry. 2021;12:653093.
    https://doi.org/10.3389/fpsyt.2021.653093
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Repeated use of prescription drugs in pediatrics: Comprehensive overview based on German claims data. Frontiers in Pharmacology. 2021;12:706682.
    https://doi.org/10.3389/fphar.2021.706682
  • Scholle O, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Kölch M. Predictors for receiving medication and/or psychotherapy in children newly diagnosed with ADHD: A longitudinal population-based cohort study. Journal of Attention Disorders. 2020;24(2):255-264.
    https://doi.org/10.1177/1087054718816172
    https://repository.publisso.de/resource/frl%3A6417559
  • Scholle O, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine. 2020;287(2):171-179.
    https://doi.org/10.1111/joim.12990
  • Vassilev ZP, Soriano-Gabarró M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtälä J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: Results from observational studies in three countries. Future Oncology. 2020;16(25):1889-1901.
    https://doi.org/10.2217/fon-2020-0315
  • Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
    https://doi.org/10.1097/JCP.0000000000000980
    https://repository.publisso.de/resource/frl%3A6423245
  • Scholle O, Jilani H, Riedel O, Banaschewski T, Hadjigeorgiou C, Hunsberger M, Iguacel I, Molnár D, Pala V, Russo P, Veidebaum T, Zaqout M, Pohlabeln H, on behalf of the I.Family consortium. Use of nutritional supplements in youth with medicated and unmedicated attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2019;29(1):58-65.
    https://doi.org/10.1089/cap.2018.0060
    https://repository.publisso.de/resource/frl%3A6423292
  • Castellsagué J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthan S. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2018;27(9):953-961.
    https://doi.org/10.1002/pds.4584
  • Scholle O, Banaschewski T, Enders D, Garbe E, Riedel O. Use and characteristics of antipsychotic/methylphenidate combination therapy in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2018;28(6):415-422.
    https://doi.org/10.1089/cap.2018.0024
    https://repository.publisso.de/resource/frl%3A6417060
  • Castellsagué J, Perez-Gutthan S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Kieler H, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2017;26(6):615-624.
    https://doi.org/10.1002/pds.4167
  • PhD-Theses

  • Scholle O. Nutzung medikamentöser und nicht-medikamentöser Therapien bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung: Primär- und Sekundärdaten-basierte Analysen. Bremen: Universität Bremen; 2020.
    https://doi.org/10.26092/elib/246
  • Presentations at scientific meetings/conferences

  • Buck C, Scholle O, Kollhorst B, Haug U. Area-level analysis of regional socio-economic factors on outpatient antibiotic prescribing including claims data from 16 million persons in Germany. 18. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2023, Würzburg.
  • Scholle O, Jobski K, Viebrock J, Haug U. Prescribing of opioid analgesics in Germany: Opposite trends when different quantification measures are used. 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-27 August 2023, Halifax, Canada. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2023;32(S1):102)
  • Schüz B, Jones C, Scholle O, Haug U. Regional variations in antibiotic prescribing in Germany: Understanding differences through an adapted theoretical domains framework. 37th Annual Conference of the European Health Psychology Society (EHPS), 4-8 September 2023, Bremen.
  • Scholle O, Rasmussen L, Reilev M, Viebrock J, Haug U. Outpatient antibiotic prescribing in early life: A population-based study comparing birth cohorts from Denmark and Germany. 29. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA), 24.-25. November 2022, Münster.
  • Scholle O, Asendorf M, Buck C, Grill S, Riedel O, Haug U. Antibiotic prescribing in children aged 0-6 years in Germany: Assessing regional variations and potential explanations based on claims data. 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-25 August 2021, online presentation. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2021;30(Suppl.1):94)
  • Scholle O, Asendorf M, Buck C, Grill S, Riedel O, Haug U. Antibiotic prescribing in children aged 0-6 years in Germany: Assessing regional variations and potential explanations based on claims data. 16. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 20.-22. September 2021, Online-Vortrag.
  • Scholle O, Grill S, Haug U. Early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. 15. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 29. September 2020, Online-Vortrag.
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. 15. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 29. September 2020, Online-Vortrag.
  • Scholle O, Kollhorst B, Haug U. Diclofenac use and cardiovascular contraindications: Risk minimisation measures lacking effectiveness in Germany - A claims data analysis. 14. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 11.-13. September 2019, Ulm.
  • Schröder C, Scholle O, Riedel O. Using administrative data to examine extent and risks of psychotropic drug use in children and adolescents. Possibilities and limitations. Congress "Health - Exploring Complexity: An Interdisciplinary Systems Approach (HEC2016)." Joint Annual Meeting of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS), the German Society for Epidemiology (DGEpi), the International Epidemiological Association - European Region (IEA-EEF) and the European Federation for Medical Informatics Association (EFMI), 28 August-2 September 2016, Munich. (Abstract published in: European Journal of Epidemiology. 2016;31(Suppl.1):S179)
  • Presentations at scientific meetings/conferences (invited)

  • Scholle O, Rasmussen L, Reilev M, Viebrock J, Haug U. Ambulante Verordnung von Antibiotika im frühen Leben: Eine bevölkerungsbasierte Studie zum Vergleich von Geburtskohorten aus Dänemark und Deutschland. Runder Tisch des Multiresistente-Erreger-Netzwerks (MRE) im Land Bremen, 17. Januar 2024, Bremen.
  • Scholle O. Regionale Unterschiede bei ambulanten Antibiotikaverordnungen auf Kreis-Ebene: Einblicke in das SARA-Projekt. Runder Tisch des Multiresistente-Erreger-Netzwerks (MRE) im Land Bremen, 16. Februar 2023, Bremen.
  • Scholle O. German Pharmacoepidemiological Research Database (GePaRD): Möglichkeiten und Grenzen. 35. Jahreskongress der Deutschen Gesellschaft für Pharmazeutische Medizin, 28.-29. März 2019, Berlin.
  • Posters at scientific meetings/conferences

  • Scholle O, Buck C, Kollhorst B, Haug U. Explaining regional variations in outpatient antibiotic prescribing: A small area analysis including over 16 million persons in Germany. 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-27 August 2023, Halifax, Canada. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2023;32(S1):602-603)
  • Bliddal M, Bachmann CJ, DosReis S, Odsbu I, Scholle O, Skurtveit S, Vivirito A, Wesselhoeft R, Scott S. So many countries, so many customs: A register-based analysis of conduct disorder prevalence and treatment patterns in four western countries. 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2022, Copenhagen, Denmark. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2022;31(Suppl. 2):578)
  • Christ P, Rischke N, Dubrall D, Scholle O, Stausberg J, Haug U, Sachs B. WOLGA: Further development, optimization and application of an algorithm for the detection of serious adverse drug reactions based on claims data - First results of a sub-analysis focusing on clostridium difficile infections. 29. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA), 24.-25. November 2022, Münster.
  • Scholle O, Rasmussen L, Reilev M, Viebrock J, Haug U. Outpatient antibiotic prescribing in early life: A population-based study comparing birth cohorts from Denmark and Germany. 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2022, Copenhagen, Denmark. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2022;31(Suppl. 2):470)
  • Scholle O, Grill S, Haug U. Changes in early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):120)
  • Scholle O, Grill S, Haug U. Changes in early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. Kinder- und Jugendmedizin aktuell, 17.-19. September 2020, Online-Poster.
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):4001)
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. Kinder- und Jugendmedizin aktuell, 17.-19. September 2020, Online-Poster.
  • Scholle O, Kollhorst B, Haug U. Are the risk minimization measures for diclofenac effective? A pre-post comparison based on German claims data. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):954)
  • Kölch M, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Scholle O. Predictors for pharmacological and psychotherapeutic treatment in children newly diagnosed with ADHD. 65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), 22-27 October 2018, Seattle, USA.
  • Scholle O, Banaschewski T, Jilani H, Riedel O, Pohlabeln H. Gebrauch von Nahrungsergänzungsmitteln bei Kindern mit medikamentös und nicht medikamentös behandelter ADHS. 13. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2018, Bremen.
  • Scholle O, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Kölch M. Predictors for pharmacological and psychotherapeutic treatment in children newly diagnosed with ADHD. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 22-26 August 2018, Prague, Czech Republic.
  • Castellsagué J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Arana A, Bui C, Laguna C, Prados-Torres A, Roso-Llorach A, Perez-Gutthan S. Impact of risk-minimization measures on the use of cilostazol in Europe. 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 26-30 August 2017, Montreal, Canada. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2017;26(Suppl.2):S428)
  • Castellsagué J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Varas-Lorenzo C, Arana A, Bui C, Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthan S. Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2016, Dublin, Ireland.

For further publications please follow this link:

  • Spotlight Poster Winner 2020 in the category of "Pediatrics"
    International Society for Pharmacoepidemiology (2020)
    Poster entitled "Changes in Early Life Exposure to Antibiotics: A Comparison of Birth Cohorts Based on German Claims Data"
  • ICPE Scholarship 2019
    International Society for Pharmacoepidemiology (2019)
    Teilnahme an der 35. International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Philadelphia, PA, USA

  • 2024 Seminar "Epidemiology I"; Bachelor's program Public Health/Health Science; Faculty 11: Human and Health Sciences; University of Bremen
  • 2023/24 Elective Module Pharmacoepidemiology in the Master's Program in Public Health/Health Sciences at TU Dresden
  • 2021/22 Elective Module Pharmacoepidemiology in the Master's Program in Public Health/Health Sciences at TU Dresden
  • May 2014 until April 2018 Subjects Pharmacy, Pharmaceutical Law & Pharmakology at the Pharmaakademie GmbH & Co. KG

The responsibility for the content of this page lies with Oliver Scholle.

Oliver Scholle

Contact

Phone:
+49 (0)421 218-56-878